SWOG clinical trial number
S1001
A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-cell Lymphoma (DLBCL)
100% Accrual
Accrual
100%
Closed
Phase
100% Accrual
Accrual
100%
Abbreviated Title
Phase II Early Stage DLBCL
Status Notes
Permanent Closure - Step 1 Registration Effective 6/1/2016 at 11:59 p.m. PST
Step 2 registration was permanently closed to accrual effective 11/30/17.
Step 2 registration was permanently closed to accrual effective 11/30/17.
Activated
07/18/2011
Closed
06/01/2016
Participants
Research committees
Lymphoma
Treatment
Cyclophosphamide
Prednisone
Vincristine
Doxorubicin
Rituximab
Yttrium-90 ibritumomab tiuxetan
Eligibility Criteria Expand/Collapse
Publication Information Expand/Collapse
Other Clinical Trials
S2308
SWOG Clinical Trial Number
Research Committee(s)
Lymphoma
Activated
08/01/2024
23% Accrual
Accrual
23%
Open
Phase
S2207
SWOG Clinical Trial Number
Research Committee(s)
Lymphoma
Activated
06/30/2023
12% Accrual
Accrual
12%
Open
Phase
CTSU/AHOD2131
SWOG Clinical Trial Number
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase